DK1875239T3 - Method of producing imaging probes using click chemistry - Google Patents

Method of producing imaging probes using click chemistry

Info

Publication number
DK1875239T3
DK1875239T3 DK06751892.8T DK06751892T DK1875239T3 DK 1875239 T3 DK1875239 T3 DK 1875239T3 DK 06751892 T DK06751892 T DK 06751892T DK 1875239 T3 DK1875239 T3 DK 1875239T3
Authority
DK
Denmark
Prior art keywords
imaging probe
candidate
library
click chemistry
identifying
Prior art date
Application number
DK06751892.8T
Other languages
Danish (da)
Inventor
Hartmuth C Kolb
Vani P Mocharla
Joseph C Walsh
Original Assignee
Siemens Medical Solutions
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Medical Solutions filed Critical Siemens Medical Solutions
Application granted granted Critical
Publication of DK1875239T3 publication Critical patent/DK1875239T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

The invention provides a method for identifying a candidate imaging probe, the method comprising: a) contacting a first library of candidate compounds with a target biomacromolecule, b) identifying a first member from the first library exhibiting affinity for the first binding site; c) contacting the first member identified from the first library affinity for the first binding site with the target biomacromolecule; d) contacting a second library of candidate compounds with the first member and the target biomacromolecule, e) reacting the complementary first functional group with the second functional group via a biomacromolecule induced click chemistry reaction to form the candidate imaging probe; f) isolating and identifying the candidate imaging probe; g) preparing the candidate imaging probe by chemical synthesis; and h) for imaging applications, converting the candidate imaging probe into an imaging probe.
DK06751892.8T 2005-04-27 2006-04-27 Method of producing imaging probes using click chemistry DK1875239T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67529005P 2005-04-27 2005-04-27
PCT/US2006/016428 WO2006116736A2 (en) 2005-04-27 2006-04-27 A method for the preparation of imaging probes using click chemistry

Publications (1)

Publication Number Publication Date
DK1875239T3 true DK1875239T3 (en) 2012-01-23

Family

ID=36954603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06751892.8T DK1875239T3 (en) 2005-04-27 2006-04-27 Method of producing imaging probes using click chemistry

Country Status (9)

Country Link
US (1) US20060269942A1 (en)
EP (1) EP1875239B1 (en)
JP (1) JP4790012B2 (en)
KR (1) KR100973156B1 (en)
AT (1) ATE527542T1 (en)
CA (1) CA2606477C (en)
DK (1) DK1875239T3 (en)
ES (1) ES2375495T3 (en)
WO (1) WO2006116736A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071718B2 (en) 2004-12-22 2011-12-06 General Electric Company Selective radiolabeling of biomolecules
WO2007018431A2 (en) * 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
US20090239760A1 (en) 2006-03-14 2009-09-24 University Of Basel Method for the Identification of New Leads for Drug Candidates
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
KR20090127433A (en) 2007-04-05 2009-12-11 지멘스 메디컬 솔루션즈 유에스에이, 인크. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
EP2823826A3 (en) * 2008-01-09 2015-03-25 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
WO2009105746A2 (en) * 2008-02-22 2009-08-27 University Of South Florida Triazoles and processes for producing the same
US9188584B2 (en) 2008-06-18 2015-11-17 California Institute Of Technology Capture agents and related compositions, methods and systems
US8618297B2 (en) 2008-07-25 2013-12-31 Basf Se Azide substituted naphthylene or rylene imide derivatives and their use as reagents in click-reactions
EP2361098B1 (en) 2008-10-31 2019-08-28 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
US8435488B2 (en) * 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2010147965A2 (en) 2009-06-15 2010-12-23 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
CN102791827B (en) 2009-11-09 2016-11-16 华盛顿大学商业化中心 Functionalization chromophoric polymers point and bioconjugate body thereof
US9649394B2 (en) 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2012121973A1 (en) * 2011-03-04 2012-09-13 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
WO2012121746A2 (en) 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
US10796494B2 (en) 2011-06-06 2020-10-06 Microsoft Technology Licensing, Llc Adding attributes to virtual representations of real-world objects
WO2013103813A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
WO2014031933A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
NZ704799A (en) 2012-08-24 2018-06-29 Univ Texas Heterocyclic modulators of hif activity for treatment of disease
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
ES2738474T3 (en) 2013-01-14 2020-01-23 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radioimageological agents
WO2014182704A2 (en) 2013-05-06 2014-11-13 The General Hospital Corporation Bioorthogonal turn-on probes
WO2015130790A2 (en) * 2014-02-25 2015-09-03 Board Of Regents, University Of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
WO2016085659A1 (en) * 2014-11-24 2016-06-02 Battelle Memorial Institute Chromatin activity precipitation method and system
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3424525A1 (en) * 1984-07-04 1986-01-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich METHOD FOR PRODUCING (ARROW UP) 1 (ARROW UP) (ARROW UP) 8 (ARROW UP) F-ALKYL AND ARYL COMPOUNDS BY HALOGEN EXCHANGE
US5519931A (en) * 1994-03-16 1996-05-28 Syncor International Corporation Container and method for transporting a syringe containing radioactive material
EP1110945A3 (en) * 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6210655B1 (en) * 1997-06-18 2001-04-03 University Of Medicine & Dentistry Of Nj Site-specific 13C-enriched reagents for diagnostic medicine by magnetic resonance imaging
US6558903B1 (en) * 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US6808308B2 (en) * 2001-05-25 2004-10-26 Scanwell Systems Removable shielding for use during neurological examinations on a whole body pet scanner
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
EP2226316B1 (en) * 2002-05-30 2016-01-13 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
DE60311879T2 (en) * 2002-12-23 2007-12-20 Astex Therapeutics Ltd., Cambridge Synthesis and screening of ligands by X-ray crystallography
US20060067879A1 (en) * 2004-09-27 2006-03-30 Schuller Hildegard M Diagnosis of diseases associated with COX-2 expression

Also Published As

Publication number Publication date
EP1875239A2 (en) 2008-01-09
WO2006116736A3 (en) 2007-02-01
CA2606477A1 (en) 2006-11-02
ATE527542T1 (en) 2011-10-15
KR20080003441A (en) 2008-01-07
ES2375495T3 (en) 2012-03-01
EP1875239B1 (en) 2011-10-05
JP4790012B2 (en) 2011-10-12
CA2606477C (en) 2013-05-28
JP2008541014A (en) 2008-11-20
WO2006116736A2 (en) 2006-11-02
US20060269942A1 (en) 2006-11-30
KR100973156B1 (en) 2010-07-30

Similar Documents

Publication Publication Date Title
DK1875239T3 (en) Method of producing imaging probes using click chemistry
DK2258870T3 (en) Process for identifying compounds that bind to a biological target molecule
Du et al. A mild, DNA-compatible nitro reduction using B2 (OH) 4
Satz Simulated screens of DNA encoded libraries: the potential influence of chemical synthesis fidelity on interpretation of structure–activity relationships
WO2007016488A3 (en) Analysis of encoded chemical libraries
WO2004087308A8 (en) Method of synthesis and testing of combinatorial libraries using microcapsules
WO2007053358A3 (en) Methods for identifying compounds of interest using encoded libraries
DK2089343T3 (en) Click chemistry for the preparation of reporter molecules
ATE493656T1 (en) METHOD FOR DIAGNOSING MULTIPLE SCLERosis
DK2336315T3 (en) Method for enzymatic coding by efficient synthesis of large libraries
WO2007120699A3 (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
EP1927584A4 (en) Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier
Wang et al. Synthesis of 7-15N-Oroidin and Evaluation of Utility for Biosynthetic Studies of Pyrrole− Imidazole Alkaloids by Microscale 1H− 15N HSQC and FTMS
Legros et al. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors
DK1800133T3 (en) Methods for screening antibody libraries
WO2019010363A8 (en) Synthesis of halichondrins
Segade et al. A short stereoselective synthesis of prepiscibactin using a SmI2-mediated Reformatsky reaction and Zn2+-induced asymmetric thiazolidine formation
Xia et al. DNA-encoded library hit confirmation: bridging the gap between on-DNA and off-DNA chemistry
Gygi et al. A triple knockout isobaric-labeling quality control platform with an integrated online database search
DK1931630T3 (en) N-substituted 3,4-alkylenedioxypyrrols, ester-substituted dihydroxypyrrols and methods for synthesizing these pyrrols
WO2004109445A3 (en) Method and apparatus for automated design of chemical synthesis routes
Baumann et al. Interrupted Curtius Rearrangements of Quaternary Proline Derivatives: A Flow Route to Acyclic Ketones and Unsaturated Pyrrolidines
Avenoza et al. SN2 Reaction of sulfur nucleophiles with hindered sulfamidates: Enantioselective synthesis of α-methylisocysteine
de Jesus Cortez et al. Disulfide-trapping identifies a new, effective chemical probe for activating the nuclear receptor human LRH-1 (NR5A2)
Greiff et al. A minimal model of peptide binding predicts ensemble properties of serum antibodies